RespiGam

RespiGam

Neonatology An IV immune globulin used to protect against RSV in high-risk children ≤ age 2 with bronchopulmonary dysplasia or prematurity. See Respiratory syncytial virus.
References in periodicals archive ?
RespiGam was approved in 1996, then supplanted with palivizumab, as a medication to reduce the burden of respiratory syncytial virus disease.
RespiGam can reduce the rate of hospitalization by 41% and prevent nasal or upper respiratory infections from becoming lower respiratory illnesses, he said.
Comment: Pediatric patients with uncorrected congenital heart disease were intentionally excluded from initial palivizumab studies because more children with the condition died in a study of another RSV treatment, RespiGam (respiratory syncytial virus immune globulin intravenous) (J.
Comment: Pediatric patients with uncorrected congenital heart disease were intentionally excluded from initial palivizum ab studies because more children with the condition died in a study of another RSV treatment, RespiGam (respiratory syncytial virus immune globulin intravenous) (J.
The vial of RespiGam must be kept refrigerated, but not frozen.
The RespiGam [TM] brand of RSV-IG was approved by the FDA on January 18, 1996, for prevention of serious lower respiratory tract infections caused by RSV in children under 24 months of age at high risk of complications from RSV infection, specifically children with bronchopulmonary dysplasia (BPD) or children who were born prematurely ([is less than or equal to] 35 weeks gestation) ("RespiGam," 1996).